Forest plot of the association of SDF1-3’A and death stratified by sources of research subjects.

<p>Forest plot of the association of SDF1-3’A and death stratified by sources of research subjects.</p

Forest plot of the association of SDF1-3’A and AIDS progression according to CDC87 criteria stratified by sources of research subjects.

<p>Forest plot of the association of SDF1-3’A and AIDS progression according to CDC87 criteria stratified by sources of research subjects.</p

Forest plot of the association of SDF1-3’A and AIDS progression according to CDC93 criteria stratified by sources of research subjects.

<p>Forest plot of the association of SDF1-3’A and AIDS progression according to CDC93 criteria stratified by sources of research subjects.</p

Forest plot of the association of SDF1-3’A and HIV susceptibility in different genetic models.

<p>(A)recessive model (B) homozygous model (C) heterozygous model (D) allele model. Studies were divided into two subgroups (High NOS scores group and Low NOS scores group) as indicated.</p

Selection process of studies included in meta-analysis.

<p>Selection process of studies included in meta-analysis.</p

Effects of different substituents R¹–R⁴ and link between ring 2 and 3 on CCR5 fusion activity.

a<p>Mean value of at least two experiments.</p>b<p>DMSO as a negative control.</p

Identification of Triptophenolide from <i>Tripterygium wilfordii</i> as a Pan-antagonist of Androgen Receptor

A compound, triptophenolide, derived from <i>Tripterygium wilfordii</i> was identified as an antiandrogen. Triptophenolide inhibits the activity of both wild-type and F876L mutant androgen receptors. Triptophenolide exhibits its antiandrogenic activity through competitive binding with androgen in the hormone-binding pocket, decreasing the expression of androgen receptor, and reducing the nuclear translocation of androgen receptor

Proposed ‘Y shape’pharmacophore model of CCR5 antagonists.

<p>Proposed ‘Y shape’pharmacophore model of CCR5 antagonists.</p

Representative structures of small-molecule CCR5 antagonists.

<p>Representative structures of small-molecule CCR5 antagonists.</p

Antiviral activity of <b>9e</b>–<b>g</b>, <b>23a</b>–<b>c</b>, and <b>23h</b>.

a<p>Mean value of two experiments.</p>b<p>DMSO as a negative control.</p